<DOC>
	<DOCNO>NCT01606189</DOCNO>
	<brief_summary>A study compare efficacy two sublingual cannabinoid base medicine extract placebo treatment chronic pain due brachial plexus injury .</brief_summary>
	<brief_title>A Study Compare Sublingual Cannabis Based Medicine Extracts With Placebo Treat Brachial Plexus Injury Pain</brief_title>
	<detailed_description>This study use three way crossover study design . Eligible patient record symptom one two week baseline period , enter three period , double blind , randomise crossover GW-1000-02 , GW-2000-02 placebo . Each period last two week , washout period . There six possible treatment sequence . The primary analysis base Box Scale-11 pain severity score record throughout study patient daily diary booklet . Blood sample take patient-volunteers begin period , measurement plasma cannabinoid concentration .</detailed_description>
	<criteria>Aged 18 year . Brachial plexus pain , least 18 month initial injury . Reported weekly brachial plexus pain required severity Visits 1 2 ; Box Scale11 pain severity score four box . A pattern pain Investigator 's opinion stable four week study entry . Stable regular medication four week study entry . A maximum tricyclic antidepressant dose 75 mg per day , applicable . No cannabinoid use ( cannabis , Marinol® Nabilone ) least seven day study entry study . If sexually active ; either use effective contraception study three month thereafter surgically sterilise , female , postmenopausal . All patient agree use barrier method contraception addition usual form oral depot contraception . Willing able undertake comply study requirement . Willing able consider understand patient information leaflet consent form give inform consent . Those patient unable read sign document manage detailed Declaration Helsinki . Willing general practitioner , consultant appropriate , inform study participation . Willing name notify Home Office participation study . Abuse strong suspicion drug abuse , include alcohol cannabis , investigator 's opinion tendency drug dependency substance abuse . Patients history abuse could include discretion investigator . Known suspect adverse reaction cannabinoids . Known suspect hypersensitivity cannabinoids excipients study medication . History type schizophrenia , psychotic illness , significant psychiatric illness depression associate chronic illness . Regular levodopa therapy ( Sinemet® , Sinemet plus® , Levodopa® , Ldopa® , Madopar® , Benserazide® ) within seven day study entry . Serious cardiovascular disorder include recent angina , uncontrolled hypertension uncontrolled symptomatic cardiac arrhythmia . History significant renal hepatic impairment show medical history indicate clinical laboratory result sample . History active epilepsy convulsion . Nerve surgery within six month study entry surgery within two month study entry . Elective surgery , procedure require general anaesthesia , plan hospital admission would take place study , hospital admission care study investigator . Terminal illness . Pregnancy , lactation expect noncompliance contraceptive measure call protocol . Participation pharmacological clinical research study 12 week study entry . Planned travel outside UK study entry end crossover phase .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>